Cover Image

Efficacy of pentoxifylline in Peyronie’s disease: Clinical case of a young man

Lucio Dell’Atti, Gianni Ughi
  • Lucio Dell’Atti
    Urology Unit, Arcispedale “S. Anna”, University of Ferrara, Italy | dellatti@hotmail.com
  • Gianni Ughi
    Urology Unit, Arcispedale “S. Anna”, University of Ferrara, Italy

Abstract

Peyronie’s disease (PD) is a localized connective tissue disorder of the tunica albuginea of the penis and its surrounding tissue which results in a painful erection, penile curvature and erectile dysfunction. The great number and variety of purposed treatments for PD is in proportion to the difficulty of its management.In fact no medical treatment is currently available to cure patients with PD. Pentoxifylline (PTX) is a non specific phosphodiesterase inhibitor with anti-inflammatory properties that has been used to treat claudication. PTX has also been used to decrease inflammation and fibrosis in kidney transplants, open heart surgery, dermatological conditions and after radiation injury. With respect to penile diseases, clinical studies have suggested that PTX decreases calcification in new-onset PD. These traits make PTX an interesting potential option for PD therapy.

Keywords

Peyronie’s Disease; Pentoxifylline; Ultrasound; Phosphodiesterase inhibitor

Full Text:

PDF
SUPPLEMENTARY MATERIAL
Submitted: 2014-10-10 11:48:21
Published: 2014-09-30 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
1040

Views:
PDF
728
SUPPLEMENTARY MATERIAL
90

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2014 Lucio Dell’Atti, Gianni Ughi

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185